Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2014-01-29 Capital/Financing Update
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a confidential draft submission of a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a preliminary prospectus for an initial public offering (IPO) of common stock by SCYNEXIS, Inc. The text includes detailed information typical of an S-1 filing such as company overview, risk factors, use of proceeds, management discussion, executive compensation, and underwriting details. The Form S-1 is a registration statement used for securities offerings and is not a financial report like an annual or quarterly report, nor is it an earnings release or a proxy statement. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, supporting a high confidence score.
2014-01-29 English
Regulatory Filings 2014
Regulatory Filings
2014-01-21 English
Capital/Financing Update 2013
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC, as indicated by the header and references to the Securities Act of 1933. It is a preliminary prospectus for an initial public offering (IPO) of common stock by SCYNEXIS, Inc. The content includes detailed information about the company, its business, risk factors, management, financial data, and the offering terms. This type of filing is a registration statement for securities offering, which falls under the category of Capital/Financing Update (CAP) because it relates to the company's fundraising activities and capital structure changes. It is not an annual or quarterly report, audit report, or earnings release. It is also not a proxy, voting results, or governance document. Therefore, the correct classification is CAP with high confidence.
2013-12-20 English
Regulatory Filings 2012
Regulatory Filings
2012-05-18 English
Regulatory Filings 2012
Regulatory Filings
2012-02-03 English
Regulatory Filings 2011
Regulatory Filings
2011-12-16 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.